GTP Scenario # 3 September 17,2005. Scenario # 3 A donor is to donate lymphocytes to a sibling 1 year after having been the PBPC donor. A donor is to.

Slides:



Advertisements
Similar presentations
ASPIRE Off-Site Visits. Rationale Why make an allowance for off-site visits in the protocol? Adherence & Retention Off-site visits Improving Clinic Flow.
Advertisements

Updates on APR Reporting for Early Childhood Transition (Indicators C-8 and B-12)
THE JOINT COMMISSION PATIENT BLOOD MANAGEMENT PERFORMANCE MEASURES
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Exception from Informed Consent in Emergency Research Designed for implementation of research in emergency settings when exception from informed consent.
Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
Questions and Answers about Bone Marrow Stem Cell Transplantation prepared by the Armenian Bone Marrow Donor Registry.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Susan N. Hocevar, MD Medical Officer Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality and Promotion Investigation Framework.
GTP Scenario # 2 September 17,2005. Scenario # 2 Dr. Good received IND approval for CD8 depletion of allogeneic PBMC for a Phase I/II clinical trial.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Communication Skills Dr. Amro Al-Hibshi Department of Orthopaedics.
Unit 5: Core Elements of HIV/AIDS Surveillance
10 Rights of Medication Administration
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Quality Assurance Programs for the Emergency Department Jim Holliman, M.D., F.A.C.E.P. Professor of Military and Emergency Medicine Uniformed Services.
Role of Clinicians in Promoting Voluntary Blood Donation Dr. Anju Verma.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Kelsey Cramer. MEET MY AUNT DONATING BONE MARROW.
CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Top 5 OPTN Policy Violations
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
Amniotic Tissue. RMG Amniotic Injectable Live cellular product cryopreserved to maintain viability and potency Anti-inflammatory and Anti-microbial actions.
Lisa Denney, MPH HRPP Assistant Director Melanie Mace, MA HRPP Education and Training Coordinator Bill Woods, PhD CAPS Policy and Ethics Core November.
CBER Review Considerations on Source Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
CBER 1 Establishment Submissions Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
ORGAN DONATION You can save a life Prepared by:. A national shortage Every 13 minutes…Every hour…Everyday… A person is added to the list 4 more are added.
RAISING THE BAR Meeting CSA Guidelines And Preparing for Health Canada
CBER Red Blood Cell Immunization Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Blood Transfusion Done by : Mrs.Eman Rizk. Definition ( Blood Transfusion ) Is the process of transferring blood or blood-based products from one person.
1 Donor’s Written Statement of Understanding Beth H. Shaz, MD Chief Medical Officer New York Blood Center Clinical Associate Professor Emory University.
GMP on blood/plasma collection establishments Group 2.
Bloodborne Pathogens First Responder. Know the regulation 29 CFR a.
FOR WHOM DOES YOUR HEART BEAT? Donate your blood! Save lives!! You only need to spare 30 minutes of your time and go to the RC Health Center!
Training Facilitators to Use the Community Health Worker Assessment and Improvement Matrix (CHW AIM) Toolkit Model Slides for Adaptation by Implementers.
Reporting Scenario # 1 September 18, Scenario # 1 A pancreas is used to prepare islets under IND. The donor was a victim in a motor vehicle accident.
An earthquake has occurred! There are many victims who have lost a lot of blood. URGENTLY I need your help URGENTLY to perform blood transfusions!
Acting on Every Donor’s Designated Decision: The Time is Now! Susan Stuart I Said Yes.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
CBER Alternative Procedures “Variances” Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 15, 2009.
UAGA Calif. Health & Safety CMS Collaborative Joint Commission 400.
Ethics in Evaluation Research & IRB. Ethical Considerations in Research 1. Voluntary Participation 2. Informed Consent 3. Risk of Harm 4. Confidentiality.
Kidney Disorders. Kidney Transplant Many consider this to be the best method of treating kidney disease. A transplant may offer the best chance.
CBER September 16, 2009 Review Considerations on Disease State Donor Programs Hoi-may Wong, BS, MT(ASCP)SBB Consumer Safety Officer CBER, OBRR, DBA.
EA Project Types Formative Assessment  Looking at what works, what doesn’t, what improvements can be made to the SLC  Utilize meeting notes, experiences,
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Extraordinary and Medically Complex Exemptions for Testing.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
Reporting Scenario # 5 September 18, Scenario # 5 Ms. Wright has malignant melanoma. Ms. Wright has malignant melanoma. Tumor obtained at resection.
Introduction Organ Transplantation Program Update Advisory Committee on Organ Transplantation November 17, 2015 Melissa Greenwald, MD Acting Director Division.
Problem Management Scenario # 2 September 17,2005.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
21 CFR Toby A. Silverman, M.D. Branch Chief, Clinical Review Branch Division of Hematology, Office of Blood December 14, 2006.
February 2010 Copyright © 2009 Mississippi Department of Education 1 School Test Coordinator Training February 15, 2010 Special Populations.
GTP Scenario # 6 September 17,2005. Scenario # 6 The Institute of America collects, processes and transplants PBPC. The Institute of America collects,
Jeopardy Game - Sample This is an example of a jeopardy game that could be used during data collection training. This is an example of a jeopardy game.
HAPLOIDENTICAL STEM CELL TRANSPLANT
1 Infectious Disease Verification to Enhance Patient Safety Operations and Safety Committee.
PRCSG Training Webinar: Budget for Industry Sponsored Studies
IMPAACT 2010 Screening Visits
IMPAACT 2010 Screening Visits
Guidance for review of studies involving HCT/Ps and IND Basics
IF THIS APPOINTMENT IS NOT KEPT YOUR SAMPLE CANNOT BE USED
GTP Scenario # 4 September 17,2005.
Erythrocytapheresis.
IMPAACT 2010 Screening Visits
MAHOPAC FALLS F.D. BLOOD DRIVE
January 2005 Regulatory Change.
OPO Committee Fall 2016.
OPO Committee Fall 2014.
Presentation transcript:

GTP Scenario # 3 September 17,2005

Scenario # 3 A donor is to donate lymphocytes to a sibling 1 year after having been the PBPC donor. A donor is to donate lymphocytes to a sibling 1 year after having been the PBPC donor. 7 Days before donation ID testing is performed (all results negative/NR). The donor is evaluated and deemed ‘eligible’. 7 Days before donation ID testing is performed (all results negative/NR). The donor is evaluated and deemed ‘eligible’. On the scheduled day of donation, the donor cannot travel to the apheresis unit due to weather conditions. On the scheduled day of donation, the donor cannot travel to the apheresis unit due to weather conditions. The collection is scheduled for the next day (8 days after the collection of the ID blood sample). The collection is scheduled for the next day (8 days after the collection of the ID blood sample). What needs to be done to administer the DLI shortly after collection? What needs to be done to administer the DLI shortly after collection?

What should be considered? Does release of this product meet the definition of “Urgent Medical Need” as defined in 21 CFR (u)? Does release of this product meet the definition of “Urgent Medical Need” as defined in 21 CFR (u)? Is there no comparable HCT/P available? Is there no comparable HCT/P available? Would the recipient suffer death or serious morbidity without the product? Would the recipient suffer death or serious morbidity without the product?

What should be considered? Does release of this product meet the definition of “Urgent Medical Need”? Does release of this product meet the definition of “Urgent Medical Need”?Yes No comparable HCT/P available? No comparable HCT/P available? True True Recipient likely to suffer death or serious morbidity without the product? Recipient likely to suffer death or serious morbidity without the product?True

What Documents Are Required? Urgent Medical Need Form Urgent Medical Need Form Includes notification of the recipient’s physician Includes notification of the recipient’s physician Recipient Consent Recipient Consent

Follow-Up Do the infectious disease tests need to be repeated? Do the infectious disease tests need to be repeated? Yes (d) Must the results be available prior to release of the product? Must the results be available prior to release of the product? Not if Urgent Medical Need documentation is obtained.

Variation What would be different if this product were intended for cryopreservation and administration 3 weeks later? What would be different if this product were intended for cryopreservation and administration 3 weeks later? Collect repeat ID samples on the day of collection and then the results would be available prior to administration. Not an urgent medical need situation. Collect repeat ID samples on the day of collection and then the results would be available prior to administration. Not an urgent medical need situation.